Bharat Parenterals shares jump 2.33% as subsidiary Innoxel Lifesciences begins commercial supply to the U.S.
Why did Bharat Parenterals Ltd shares jump today?
Bharat Parenterals Ltd shares surged 2.33% to ₹1769.25 as of Wednesday, 01:51 PM, after the company announced a significant development for its material subsidiary, Innoxel Lifesciences Private Limited. Innoxel has officially commenced commercial supply to the United States market. The first product, manufactured at Innoxel's finished dosage facility in Vadodara, Gujarat, under a contract manufacturing (CMO) arrangement, was launched in the U.S. by its sponsor partner on October 20, 2026. This marks an important milestone for Bharat Parenterals as it expands its international footprint.
The commencement of U.S. commercial supply signals a shift for Innoxel Lifesciences from relying on licensing income to generating recurring commercial revenue through active product supply. This transition is expected to provide more stable and predictable earnings going forward. The company has also indicated that additional CMO product launches are lined up over the next two quarters and into FY28, suggesting a strong pipeline of commercial activity ahead. The announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with the press release titled "Innoxel Lifesciences commences U.S. commercial supply with launch of its first CMO product" submitted to the BSE under Scrip Code 541096.
The positive market reaction reflects investor confidence in the company's growth strategy. The U.S. market is one of the largest pharmaceutical markets globally, and securing commercial supply agreements there is a meaningful achievement for any Indian pharmaceutical company. With more launches planned in the coming quarters, investors appear optimistic about the recurring revenue potential this new phase of business could bring to Bharat Parenterals and its subsidiary.
What does Bharat Parenterals Ltd do?
Bharat Parenterals Limited is a company with a material subsidiary, Innoxel Lifesciences Private Limited, which operates a finished dosage manufacturing facility in Vadodara, Gujarat. Innoxel is engaged in contract manufacturing (CMO) arrangements, producing finished dosage pharmaceutical products. As of October 2026, Innoxel commenced commercial supply to the United States market, with its first CMO product being launched in the U.S. by its sponsor partner on October 20, 2026.
The company operates within the pharmaceutical sector, with a focus on finished dosage manufacturing and contract manufacturing services. Through its subsidiary Innoxel Lifesciences, Bharat Parenterals has expanded its commercial footprint into the United States market, manufacturing products at its Vadodara facility for supply to U.S.-based sponsor partners. The company is listed on BSE Limited under Scrip Code 541096 and is subject to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with Mr. Sharmin Soni serving as Company Secretary & Compliance Officer.
Bharat Parenterals Ltd Financials
In CroresBharat Parenterals Ltd reported a quarterly revenue of ₹99.62 Crores in March 2026, which declined to ₹93.74 Crores in June 2026, marking a sequential drop of approximately 5.9%. However, the company's profitability showed a notable turnaround during the same period, swinging from a net loss of ₹4.8 Crores in March 2026 to a net profit of ₹1.01 Crores in June 2026. While the top line witnessed a downward trend, the reversal from a loss to profitability indicates an improvement in cost management or operational efficiency in the June 2026 quarter. Overall, the financials reflect a mixed trend — revenue contraction alongside a positive shift in bottom-line performance.
Bharat Parenterals Ltd Shareholding Pattern
Promoter holding stands at 67.2% of the total share capital. Foreign Institutional Investors (FIIs) hold 0.11% stake in the company, while Domestic Institutional Investors (DIIs) hold 1.29%. Public shareholders hold the remaining 31.4% stake in Bharat Parenterals Ltd.
Bharat Parenterals Ltd FAQs
Q: Why did Bharat shares jump 2.33% today?
Press Release on Commencement of Commercial Supply to the U.S by Innoxel Lifesciences Private Limited, Material Subsidiary Company of Bharat Parenterals Limited.. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Bharat Parenterals Ltd?
As per the latest data, promoters hold 67.2% stake in Bharat Parenterals Ltd, while FII holding stands at 0.11%. Domestic institutional investors hold 1.29%, and public shareholders account for 31.4% of the equity.
Q: What is the current stock price of Bharat Parenterals Ltd?
Bharat Parenterals Ltd shares are currently trading at ₹1769.25, recording a gain of 2.33% from the previous close.
Q: What is the market capitalization of Bharat Parenterals Ltd?
The company currently has a market capitalization of ₹1219.36 crore, reflecting its valuation in the Indian equity market.